Interpreting | 2010.03.04
Repros Receives Official FDA Minutes from Type C Androxal® Meeting
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received the FDA’s version of the minutes of the Type C meeting held on January 25, 2010. The minutes confirmed the Company’s interpretation of the points the Agency made during the meeting. In correspondence from the FDA prior to the meeting the Agency noted that they could not currently agree with the Company’s stated indication for the use of Androxal® in
For more information, please visit
http://www.businesswire.com/news/home/20100303006901/en
